Register for our free email digests:
Shionogi & Co. Ltd.
www.shionogi.co.jp
Latest From Shionogi & Co. Ltd.
Kissei Discussing Rovatirelin Path After Mixed Phase III Results
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.
EU 2019 Approvals: Novel Therapies Make Strong Showing
Bluebird bio’s gene therapy Zynteglo, Akcea’s antisense drug Waylivra and BioMarin’s enzyme substitution therapy Palynziq were among the novel innovative medicines that were approved in Europe in 2019.
Five Topics That Shaped Japan Pharma In 2019
Looking back on the top stories about Japan in Scrip and the Pink Sheet over 2019, it is hard to avoid the continued dominance of corporate transactions - in particular those involving Takeda.
FDA CRL Delays ViiV’s Long-Acting Cabotegravir Regimen
ViiV Healthcare will not be able to launch its cabotegravir and rilpivirine long-acting HIV treatment in January after receiving an FDA Complete Response Letter.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Cancer
- Gynecological, Urological
- Immune Disorders
- Infectious & Viral Diseases
- Metabolic Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
Asia
-
Pacific Rim
-
Japan
-
Japan
-
Pacific Rim
-
Asia
- Company Type
- Top Japanese Pharma
- Parent & Subsidiaries
- Shionogi & Co. Ltd.
- Senior Management
- Isao Teshirogi, PhD, Pres. & CEO
- Contact Info
-
Shionogi & Co. Ltd.
Phone: (81) 6 6202 2161
1-8, Doshomachi 3-chome
Chuo-ku
Osaka, 541 0045
Japan
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice